BioInvent International AB (publ)
BOVNFOTCHealthcare● Active
$6.63
+$3.34(+101.61%)
Market Cap$436282920
P/E Ratio—
52W High$6.63
52W Low$3.2886
BioInvent International AB (publ) (BOVNF) · Income Statement
Annual, quarterly, or TTM views · SEC 10-K & 10-Q via FMP · adjust period and M/B/T below.
FMP · BOVNF · as of 2026-06-09
Financial statements
Revenue · Gross Profit · Net Income
| Breakdown | 2025-12 | 2024-12 | 2023-12 | 2022-12 | 2021-12 |
|---|---|---|---|---|---|
| Revenue | |||||
| Revenue | $0.23B | $0.04B | $0.07B | $0.33B | $0.02B |
| Cost of Revenue | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Gross Profit | $0.23B | $0.04B | $0.07B | $0.33B | $0.02B |
| Gross Margin %(computed) | 100.25% | 100.00% | 100.00% | 100.00% | 100.00% |
| Operating Expenses | |||||
| R&D Expenses | $0.50B | $0.46B | $0.39B | $0.33B | $0.26B |
| G&A Expenses | $0.07B | $0.06B | $0.05B | $0.05B | $0.04B |
| Total Operating Expenses | $0.58B | $0.52B | $0.44B | $0.38B | $0.30B |
| Operating Income | ($0.35B) | ($0.47B) | ($0.37B) | ($0.05B) | ($0.28B) |
| Operating Margin %(computed) | -155.14% | — | -517.68% | -15.61% | — |
| Interest Income | $0.02B | $0.04B | $0.04B | $0.01B | $0.00B |
| Interest Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Income Before Tax | ($0.33B) | ($0.43B) | ($0.33B) | ($0.04B) | ($0.28B) |
| Income Tax Expense | $0.00B | $0.00B | $0.00B | $0.00B | $0.00B |
| Net Income | ($0.33B) | ($0.43B) | ($0.33B) | ($0.03B) | ($0.28B) |
| Net Margin %(computed) | -146.96% | -960.87% | -462.22% | -10.45% | — |
| Per Share & EBITDA | |||||
| EPS (Basic) | $-5.07 | $-6.53 | $-5.02 | $-0.55 | $-5.15 |
| Wtd Avg Shares | 0.07B | 0.07B | 0.07B | 0.06B | 0.05B |
| EBITDA | ($0.33B) | ($0.46B) | ($0.31B) | ($0.03B) | ($0.26B) |
| EBITDA Margin %(computed) | -146.37% | — | -437.59% | -8.32% | — |
Data source: Financial Modeling Prep · Last updated: 2026-06-09 · SEK · B
Explore more BioInvent International AB (publ) data
About BioInvent International AB (publ) (BOVNF) Income Statement
BioInvent International AB (publ) (BOVNF) income statement data is sourced from SEC Form 10-K and 10-Q filings. For fiscal year 2025, BOVNF reported revenue of $0.23B, gross profit of $0.23B (gross margin 100.25%), and net income of ($0.33B) — a net profit margin of -146.96%.
Frequently asked questions
BOVNF · 4 questionsBioInvent International AB (publ) (BOVNF) reported revenue of $0.23B for 2025, up 405.6% year-over-year.
BOVNF revenueBOVNF salesannual revenue YoYincome statement
· Source: FMP /stable/income-statement · SEC EDGAR Form 10-K & 10-Q · As of 2026-06-09